As Reuters reports, “virtually all of the experts who wrote favorably about GlaxoSmithKline Plc’s troubled diabetes drug Avandia (rosiglitazone) had financial ties to drug makers, a finding that shows the need for reform of such relationships, U.S. researchers said on Thursday.”
Mayo’s Dr. Victor Montori told Reuters:
“It was almost three to four times more likely that somebody who had a relationship with a pharmaceutical company had a favorable opinion about the medication. If you were to look at the proportion of people with favorable opinions, 94 percent of them had a relationship with a pharmaceutical company. If you were to look at the folks with an unfavorable opinion, 28 percent had a relationship with a pharmaceutical company.”
Because the team found that a quarter of the scientific papers about Avandia did not disclose that the authors had financial relationships with the drug company, they wrote that the findings “underscore the need for further changes in disclosure procedures in order for the scientific record to be trusted.”
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Comments are closed.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like